Zeenat Bio has successfully concluded its C+ round of financing, securing a total of 280 million yuan. This funding round was jointly spearheaded by Sungene Biotech, KingMed Diagnostics, Shengweirongquan, and Jinhe Capital, with additional participation from Wojie Capital, Haikou Junxin, Shuangye Venture Capital, and Qianhe Capital. The proceeds from this financing will be dedicated to fostering a robust commercial ecosystem and fueling global expansion efforts, ultimately aiming to bolster the widespread adoption of domestic sequencing equipment. Zeenat Bio has introduced an array of high-performance sequencers and secured multiple medical device certifications, extending its business reach to over 50 countries and regions worldwide. Investors have reiterated their unwavering support for Zeenat Bio's innovative strides in gene sequencing technology and its strategic global market positioning.